Diamond Hill Capital Management Inc. grew its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 50.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,075,604 shares of the medical research company’s stock after acquiring an additional 360,911 shares during the period. Diamond Hill Capital Management Inc. owned 0.28% of Thermo Fisher Scientific worth $203,504,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Reinhart Partners Inc. boosted its stake in shares of Thermo Fisher Scientific by 0.6% during the second quarter. Reinhart Partners Inc. now owns 3,430 shares of the medical research company’s stock valued at $598,000 after purchasing an additional 20 shares in the last quarter. Covington Capital Management boosted its stake in shares of Thermo Fisher Scientific by 0.9% during the second quarter. Covington Capital Management now owns 2,144 shares of the medical research company’s stock valued at $374,000 after purchasing an additional 20 shares in the last quarter. Investment Centers of America Inc. boosted its stake in shares of Thermo Fisher Scientific by 1.6% during the second quarter. Investment Centers of America Inc. now owns 1,317 shares of the medical research company’s stock valued at $230,000 after purchasing an additional 21 shares in the last quarter. Fort Washington Investment Advisors Inc. OH boosted its stake in shares of Thermo Fisher Scientific by 0.4% during the second quarter. Fort Washington Investment Advisors Inc. OH now owns 6,250 shares of the medical research company’s stock valued at $1,090,000 after purchasing an additional 23 shares in the last quarter. Finally, Azimuth Capital Management LLC boosted its stake in shares of Thermo Fisher Scientific by 0.8% during the first quarter. Azimuth Capital Management LLC now owns 3,210 shares of the medical research company’s stock valued at $493,000 after purchasing an additional 25 shares in the last quarter. Institutional investors and hedge funds own 83.78% of the company’s stock.

In related news, Director C Martin Harris sold 360 shares of the firm’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total transaction of $65,149.20. Following the completion of the transaction, the director now owns 5,312 shares of the company’s stock, valued at $961,312.64. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jim P. Manzi sold 11,318 shares of the firm’s stock in a transaction on Friday, August 18th. The stock was sold at an average price of $172.94, for a total transaction of $1,957,334.92. Following the transaction, the director now directly owns 38,757 shares of the company’s stock, valued at approximately $6,702,635.58. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,738 shares of company stock valued at $4,021,512. 0.49% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Inc (NYSE:TMO) opened at $188.21 on Tuesday. The stock has a market cap of $74,657.32, a price-to-earnings ratio of 20.46, a price-to-earnings-growth ratio of 1.71 and a beta of 1.08. Thermo Fisher Scientific Inc has a fifty-two week low of $139.07 and a fifty-two week high of $201.20. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $5.03 billion. During the same quarter last year, the company posted $2.03 earnings per share. The firm’s revenue was up 13.9% compared to the same quarter last year. sell-side analysts expect that Thermo Fisher Scientific Inc will post 9.36 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be issued a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.19%.

A number of equities analysts have recently issued reports on TMO shares. Leerink Swann increased their price objective on shares of Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a research note on Monday, October 9th. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 target price for the company in a research report on Thursday, September 21st. Bank of America Corporation reissued a “buy” rating and set a $210.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. Cowen and Company reissued an “outperform” rating and set a $220.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Sunday, September 10th. Finally, Deutsche Bank AG set a $226.00 target price on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Thursday, October 26th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $205.71.

COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/thermo-fisher-scientific-inc-tmo-shares-bought-by-diamond-hill-capital-management-inc/1701904.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.